cefditoren (spectracef) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefditoren pivoxil is a semi-synthetic cephalosporin antibiotic for oral administration. It is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, infection of skin and/or subcutaneous tissue, and pharyngitis/tonsillitis. Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Common adverse reactions include diarrhea, nausea and candida vaginitis. Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides or co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal. Co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren.   NCATS

Chemistry

  • SMILES: CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/C3=C(C)N=CS3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4
  • InChIKey: KMIPKYQIOVAHOP-YLGJWRNMSA-N
  • Mol. Mass: 506.578
  • ALogP: 1.29
  • ChEMBL Molecules:
    cefditoren  
    cefditoren pivoxil  
More Chemistry

Pharmacology

Alternative names

5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(3(z),6alpha,7beta(z)))- | (-)-(6r,7r)-2,2-dimethylpropionyloxymethyl 7-((z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-((z)-2-(4-methylthiazol-5-yl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate | 7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(2-(4-methylthiazol-5-yl)ethenyl)cephem-4-carboxylic acid pivaloyloxymethyl ester | cdtr-pi | cefditoren | cefditoren pivaloyloxymethyl ester | cefditoren pivoxil | cefditoren pivoxyl | cefditoren, sodium salt, (6r-(3(z),6alpha,7beta(z)))-isomer | ceftidoren | me 1206 | me-1206 | me1207 | me 1207 | me-1207 | meiact | spectracef

Organizations (7)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (7)


 

Bronchitis, Chronic

Infections

Pharyngitis

Pneumonia, Bacterial (approved 2001)

Skin Diseases, Bacterial (approved 2001)

Tonsillitis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

COVID-19 (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Sinusitis (Phase 4)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue